Glycan Release Service
Glycosylation: The Foundation for Advanced Glycobiology
Most proteins are post-translationally, and the most important modification of many secretory and membrane-related proteins in eukaryotic cells is glycosylation, that is, the attachment of one or more glycan chains. Glycan chains of glycoprotein are mainly connected to Asn residues of peptide backbone by N-glycopeptide bond or Ser / Thr residues by O-glycopeptide bond.
The glycans attached to proteins have structural diversity, and each glycosylated polypeptide is usually associated with a population of different glycan structures, which leads to the observation of considerable glycosylation heterogeneity in many glycoproteins. Current techniques generally cannot analyze the complete glycoproteins. Therefore, oligosaccharide analysis is mainly carried out after the release of the oligosaccharides from the polypeptide. Glycan release technology is based on enzyme or chemical programming. Each technology has its own advantages, and the choice of technology will depend on the type of glycosylation and the nature and quantity of samples.
CD BioGlyco stands at the forefront of glycomics research, offering a comprehensive and highly specialized glycan release service. Leveraging our expertise, we provide robust and reliable solutions that are foundational for in-depth glycan analysis. This essential preparatory step is key to unlocking the full biological potential encoded within glycosylation, ensuring the isolation of intact glycans for precise downstream characterization by advanced analytical platforms.
Comprehensive Glycan Release: Tailoring Solutions for Every Glycosylation Challenge
CD BioGlyco offers an extensive array of glycan release options, meticulously designed to cater to the diverse requirements of glycomics research and development. Our comprehensive service scope ensures that virtually any glycosylation linkage is effectively targeted and analyzed.
Our enzymatic release services leverage highly specific enzymes to ensure precise and efficient cleavage, minimizing sample degradation and preserving glycan integrity.
Utilizing PNGase F, we provide highly efficient and reproducible release of N-linked glycans from a wide range of glycoproteins. This method is the preferred choice for applications requiring intact N-glycan structures for subsequent profiling and structural elucidation.
We employ specific fucosidases to selectively cleave terminal fucose residues. This service is invaluable for studying the role of fucosylation in biological processes, such as inflammation and cancer, or for preparing glycans for further analysis by removing this common modification.
Our service includes the use of highly purified galactosidases for the enzymatic removal of terminal galactose residues. This is crucial for structural determination, especially in complex glycans, and for investigating the biological significance of galactosylation, particularly relevant in areas like blood group antigens and immune regulation.
Targeting α-N-acetylgalactosaminidase, this service enables the selective release of N-acetylgalactosamine. This is particularly useful for dissecting specific glycan linkages and for research into O-linked glycosylation pathways.
For O-linked glycans, we employ O-glycosidase and other broad-specificity enzymes to facilitate their release from various O-glycosylated proteins. This service provides a gentle yet effective way to obtain O-glycans for downstream analysis, particularly for structures amenable to enzymatic cleavage.
Focusing on one of the most common O-glycan core structures, our specialized service ensures the efficient enzymatic release of core-1 O-glycans, which are vital in cell adhesion, signaling, and disease. This targeted approach allows for focused analysis of these specific and biologically significant structures.
Using sialidases, we offer precise enzymatic removal of terminal sialic acid residues. This is essential for understanding the roles of sialylation in cellular communication, viral entry, and immune evasion, and for preparing glycans for further analysis where desialylation is required.
Our chemical release methods provide robust alternatives for glycans resistant to enzymatic digestion or for comprehensive release strategies.
- Hydrazinolysis: A powerful chemical method for the release of both N-linked and, to a lesser extent, O-linked glycans. This technique is particularly valuable for the efficient release of glycans from difficult-to-denature or insoluble glycoproteins.
- Reductive β-Elimination: The gold standard for the chemical release of O-linked glycans. This method is highly effective for a wide range of O-glycan structures, including those found on mucins and other heavily O-glycosylated proteins. The inclusion of a reducing agent prevents glycan "peeling", ensuring the integrity of the released structures for subsequent analysis.
Workflow
Publication Data
Journal: Frontiers in Molecular Biosciences
IF: 4.0
Published: 2022
Results: The paper highlights the effectiveness of chemical methods for glycan release, exploring the release of protein N-glycans via effectors of a Hofmann carboxamide rearrangement. This study demonstrates that known Hofmann catalysts, such as 1,3-dichloro-5,5-dimethylhydantoin, hypervalent organoiodine compounds like diacetoxy-iodobenzene, and in-situ hypobromite generation, are all capable of releasing protein-bound N-glycans in good yield. These findings suggest that the oxidative release of N-glycans proceeds through the initial steps of a Hofmann carboxamide rearrangement. Notably, the in-situ generation of hypobromite using bromide provides a consistent and defined amount of reagent for rapid N-glycan release, suitable for both analytical and preparative applications.
Fig.1 Similarities between the hypochlorite method and the Hofmann carboxamide rearrangement. (Kasim, et al., 2022)
Applications
- Biopharmaceutical development: Essential for characterization of therapeutic proteins (e.g., antibodies, recombinant proteins), biosimilar development, and quality control of glycoconjugate vaccines.
- Biomarker discovery: Identification of novel glycan biomarkers for early disease detection, progression monitoring, and therapeutic response assessment in various diseases, including cancer, autoimmune disorders, and infectious diseases.
- Fundamental glycoscience research: Deciphering the roles of glycans in cell-cell interactions, immune recognition, host-pathogen interactions, protein folding, and other fundamental biological processes.
Advantages
- Comprehensive expertise: Our team possesses deep scientific knowledge in both enzymatic and chemical glycan release methodologies. We expertly navigate the complexities of diverse glycan structures and sample matrices to provide optimal solutions.
- Tailored solutions: We understand that each research project is unique. Our services are highly customizable, offering flexible options for both N-glycan and O-glycan release, alongside specific monosaccharide targeting.
- Uncompromising quality and reproducibility: We adhere to stringent quality control standards at every stage of the workflow. Our optimized protocols and state-of-the-art facilities guarantee highly reproducible and reliable glycan release, providing confidence in your downstream analytical results.
Frequently Asked Questions
CD BioGlyco is committed to accelerating your research with our unparalleled glycan release service and comprehensive glycomics solutions. Please feel free to contact us our team of experienced scientists is ready to discuss your specific project needs and provide tailored recommendations.
Associated Services
To further support your comprehensive glycomics research and development endeavors, CD BioGlyco offers a suite of complementary services designed to provide end-to-end solutions for glycan analysis and beyond.
- Glycan Separation and Purification Service
- Glycomic Characterization Service
- Glycoprotein Quantification
- Site Occupation
Reference
- Kasim, M.; et al. Release of protein N-glycans by effectors of a Hofmann carboxamide rearrangement. Frontiers in Molecular Biosciences. 2022, 9: 983679. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




